Morgan Stanley
JSPR icon

Morgan Stanley’s Jasper Therapeutics JSPR Stock Holding History

Morgan Stanley’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$726 Sell
1,724
-1,331,696
-100% -$997K ﹤0.01% 7558
2026
Q1 		$1.17M Sell
1,333,420
-636,365
-32% -$883K ﹤0.01% 5056
2025
Q4 		$3.6M Buy
1,969,785
+1,179,825
+149% +$2.37M ﹤0.01% 4419
2025
Q3 		$1.88M Buy
789,960
+20,210
+3% +$61.3K ﹤0.01% 4828
2025
Q2 		$4.27M Buy
769,750
+115,766
+18% +$570K ﹤0.01% 4183
2025
Q1 		$2.81M Buy
653,984
+49,192
+8% +$327K ﹤0.01% 4383
2024
Q4 		$12.9M Buy
604,792
+39,070
+7% +$813K ﹤0.01% 3170
2024
Q3 		$10.6M Buy
565,722
+256,303
+83% +$5.1M ﹤0.01% 3384
2024
Q2 		$7.02M Buy
309,419
+133,002
+75% +$3.19M ﹤0.01% 3610
2024
Q1 		$5.18M Buy
176,417
+6,462
+4% +$115K ﹤0.01% 3886
2023
Q4 		$1.34M Buy
169,955
+91,867
+118% +$617K ﹤0.01% 4767
2023
Q3 		$547K Buy
78,088
+45,933
+143% +$561K ﹤0.01% 5128
2023
Q2 		$441K Sell
32,155
-5,652
-15% -$84K ﹤0.01% 5283
2023
Q1 		$684K Buy
37,807
+37,502
+12,296% +$693K ﹤0.01% 5074
2022
Q4 		$1.47K Sell
305
-8
-3% -$54 ﹤0.01% 7416
2022
Q3 		$2K Buy
313
+13
+4% +$238 ﹤0.01% 7473
2022
Q2 		$6K Sell
300
-128
-30% -$3.65K ﹤0.01% 7361
2022
Q1 		$15K Sell
428
-29,451
-99% -$1.33M ﹤0.01% 7262
2021
Q4 		$2.35M Buy
29,879
+18,993
+174% +$1.78M ﹤0.01% 4455
2021
Q3 		$1.12M Buy
+10,886
New +$1.11M ﹤0.01% 4981

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's JSPR Position: Q2 2026 in Review

Morgan Stanley reduced its Jasper Therapeutics (JSPR) stake by 100% in Q2 2026, selling an estimated $997K and leaving 1,724 shares worth $726. The position accounts for ﹤0.01% of the portfolio, ranked #7558.

Morgan Stanley first reported a position in JSPR in Q3 2021 and has held it in 20 quarters since. The position peaked at $12.9M in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Morgan Stanley held 1,724 shares of Jasper Therapeutics worth $726 as of Q2 2026.
  • Morgan Stanley sold 1,331,696 Jasper Therapeutics shares in Q2 2026, an estimated $997K.
  • Jasper Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7558 holding.
  • Morgan Stanley first reported a position in Jasper Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Jasper Therapeutics position peaked at $12.9M in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.